Ruthenium-based complexes show double benefits in UT Arlington cancer research

A University of Texas at Arlington team researching ruthenium compounds as possible anti-cancer drugs has discovered a way to make their complexes more effective against cancer cells and less toxic to healthy cells in lab tests. Professor Frederick MacDonnell, of the UT Arlington Department of Chemistry and Biochemistry, presented his work this month at the 24th International Symposium on Chiral Discrimination in Fort Worth. His presentation was called: “In vitro and in vivo responses to the chirality of ruthenium-based anti-cancer drugs.” Platinum-based drugs are currently the first